Results of radiotherapy for chemodectomas

S. E. Schild, R. L. Foote, S. J. Buskirk, J. S. Robinow, F. F. Bock, R. E. Cupps, J. D. Earle

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

Between 1974 and 1988, 10 Mayo Clinic patients had unresectable, locally recurrent, or partially resected chemodectomas. Of these 10 tumors, 9 were confirmed pathologically, and 1 was diagnosed clinically. The chemodectoma was located in the jugular bulb in five patients, the middle ear in three, and the carotid body in two. The following symptoms were noted: tinnitus (in eight patients), loss of hearing (in six), hoarseness (in six), dysphagia (in four), pain (in three), and alteration of mental status (in one). Many patients had more than one symptom. Treatment was delivered with megavoltage photons and electrons; total doses ranged from 16.2 to 52 Gy (median, 46 Gy), and the daily doses ranged from 1.6 to 2.4 Gy. Follow-up among the nine survivors ranged from 3 1/2 to 16 years (median, 7 1/2 years). In one patient, the response could not be assessed because the patient died of renal failure 4 months after treatment. All nine assessable patients had decreased symptoms and objective control of the tumor (no evidence of progression of disease). Of the nine assessable patients, four had complete responses, one had a partial response, and four had stable disease. No patient experienced progression of disease after radiotherapy. We conclude that radiotherapy for chemodectomas yields successful results-namely, decreased symptoms and objective control of the tumor.

Original languageEnglish (US)
Pages (from-to)537-540
Number of pages4
JournalMayo Clinic Proceedings
Volume67
Issue number6
StatePublished - 1992

Fingerprint

Extra-Adrenal Paraganglioma
Radiotherapy
Disease Progression
Carotid Body
Hoarseness
Neoplasms
Tinnitus
Middle Ear
Deglutition Disorders
Photons
Hearing Loss
Renal Insufficiency
Survivors
Neck
Electrons

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Schild, S. E., Foote, R. L., Buskirk, S. J., Robinow, J. S., Bock, F. F., Cupps, R. E., & Earle, J. D. (1992). Results of radiotherapy for chemodectomas. Mayo Clinic Proceedings, 67(6), 537-540.

Results of radiotherapy for chemodectomas. / Schild, S. E.; Foote, R. L.; Buskirk, S. J.; Robinow, J. S.; Bock, F. F.; Cupps, R. E.; Earle, J. D.

In: Mayo Clinic Proceedings, Vol. 67, No. 6, 1992, p. 537-540.

Research output: Contribution to journalArticle

Schild, SE, Foote, RL, Buskirk, SJ, Robinow, JS, Bock, FF, Cupps, RE & Earle, JD 1992, 'Results of radiotherapy for chemodectomas', Mayo Clinic Proceedings, vol. 67, no. 6, pp. 537-540.
Schild SE, Foote RL, Buskirk SJ, Robinow JS, Bock FF, Cupps RE et al. Results of radiotherapy for chemodectomas. Mayo Clinic Proceedings. 1992;67(6):537-540.
Schild, S. E. ; Foote, R. L. ; Buskirk, S. J. ; Robinow, J. S. ; Bock, F. F. ; Cupps, R. E. ; Earle, J. D. / Results of radiotherapy for chemodectomas. In: Mayo Clinic Proceedings. 1992 ; Vol. 67, No. 6. pp. 537-540.
@article{70399facf74b4783a5dc52b413eb863b,
title = "Results of radiotherapy for chemodectomas",
abstract = "Between 1974 and 1988, 10 Mayo Clinic patients had unresectable, locally recurrent, or partially resected chemodectomas. Of these 10 tumors, 9 were confirmed pathologically, and 1 was diagnosed clinically. The chemodectoma was located in the jugular bulb in five patients, the middle ear in three, and the carotid body in two. The following symptoms were noted: tinnitus (in eight patients), loss of hearing (in six), hoarseness (in six), dysphagia (in four), pain (in three), and alteration of mental status (in one). Many patients had more than one symptom. Treatment was delivered with megavoltage photons and electrons; total doses ranged from 16.2 to 52 Gy (median, 46 Gy), and the daily doses ranged from 1.6 to 2.4 Gy. Follow-up among the nine survivors ranged from 3 1/2 to 16 years (median, 7 1/2 years). In one patient, the response could not be assessed because the patient died of renal failure 4 months after treatment. All nine assessable patients had decreased symptoms and objective control of the tumor (no evidence of progression of disease). Of the nine assessable patients, four had complete responses, one had a partial response, and four had stable disease. No patient experienced progression of disease after radiotherapy. We conclude that radiotherapy for chemodectomas yields successful results-namely, decreased symptoms and objective control of the tumor.",
author = "Schild, {S. E.} and Foote, {R. L.} and Buskirk, {S. J.} and Robinow, {J. S.} and Bock, {F. F.} and Cupps, {R. E.} and Earle, {J. D.}",
year = "1992",
language = "English (US)",
volume = "67",
pages = "537--540",
journal = "Mayo Clinic Proceedings",
issn = "0025-6196",
publisher = "Elsevier Science",
number = "6",

}

TY - JOUR

T1 - Results of radiotherapy for chemodectomas

AU - Schild, S. E.

AU - Foote, R. L.

AU - Buskirk, S. J.

AU - Robinow, J. S.

AU - Bock, F. F.

AU - Cupps, R. E.

AU - Earle, J. D.

PY - 1992

Y1 - 1992

N2 - Between 1974 and 1988, 10 Mayo Clinic patients had unresectable, locally recurrent, or partially resected chemodectomas. Of these 10 tumors, 9 were confirmed pathologically, and 1 was diagnosed clinically. The chemodectoma was located in the jugular bulb in five patients, the middle ear in three, and the carotid body in two. The following symptoms were noted: tinnitus (in eight patients), loss of hearing (in six), hoarseness (in six), dysphagia (in four), pain (in three), and alteration of mental status (in one). Many patients had more than one symptom. Treatment was delivered with megavoltage photons and electrons; total doses ranged from 16.2 to 52 Gy (median, 46 Gy), and the daily doses ranged from 1.6 to 2.4 Gy. Follow-up among the nine survivors ranged from 3 1/2 to 16 years (median, 7 1/2 years). In one patient, the response could not be assessed because the patient died of renal failure 4 months after treatment. All nine assessable patients had decreased symptoms and objective control of the tumor (no evidence of progression of disease). Of the nine assessable patients, four had complete responses, one had a partial response, and four had stable disease. No patient experienced progression of disease after radiotherapy. We conclude that radiotherapy for chemodectomas yields successful results-namely, decreased symptoms and objective control of the tumor.

AB - Between 1974 and 1988, 10 Mayo Clinic patients had unresectable, locally recurrent, or partially resected chemodectomas. Of these 10 tumors, 9 were confirmed pathologically, and 1 was diagnosed clinically. The chemodectoma was located in the jugular bulb in five patients, the middle ear in three, and the carotid body in two. The following symptoms were noted: tinnitus (in eight patients), loss of hearing (in six), hoarseness (in six), dysphagia (in four), pain (in three), and alteration of mental status (in one). Many patients had more than one symptom. Treatment was delivered with megavoltage photons and electrons; total doses ranged from 16.2 to 52 Gy (median, 46 Gy), and the daily doses ranged from 1.6 to 2.4 Gy. Follow-up among the nine survivors ranged from 3 1/2 to 16 years (median, 7 1/2 years). In one patient, the response could not be assessed because the patient died of renal failure 4 months after treatment. All nine assessable patients had decreased symptoms and objective control of the tumor (no evidence of progression of disease). Of the nine assessable patients, four had complete responses, one had a partial response, and four had stable disease. No patient experienced progression of disease after radiotherapy. We conclude that radiotherapy for chemodectomas yields successful results-namely, decreased symptoms and objective control of the tumor.

UR - http://www.scopus.com/inward/record.url?scp=0026716169&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026716169&partnerID=8YFLogxK

M3 - Article

VL - 67

SP - 537

EP - 540

JO - Mayo Clinic Proceedings

JF - Mayo Clinic Proceedings

SN - 0025-6196

IS - 6

ER -